LDP 392

Drug Profile

LDP 392

Alternative Names: CMI 392

Latest Information Update: 07 May 2008

Price : $50

At a glance

  • Originator Millennium Pharmaceuticals; University of Virginia
  • Class Skin disorder therapies; Small molecules
  • Mechanism of Action 5-lipoxygenase inhibitors; Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Asthma; Atopic dermatitis; Psoriasis; Skin disorders

Most Recent Events

  • 22 Oct 2003 No development reported - Phase-II for Atopic dermatitis in USA (Topical)
  • 22 Oct 2003 No development reported - Phase-II for Psoriasis in USA (Topical)
  • 22 Oct 2003 No development reported - Preclinical for Adult respiratory distress syndrome in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top